logo
Plus   Neg
Share
Email

AstraZeneca: European Commission Approves Qtrilmet For Type-2 Diabetes

AstraZeneca (AZN.L,AZN) reported that the European Commission has approved Qtrilmet modified-release tablets to improve glycaemic control in adults with type-2 diabetes. The EC has approved Qtrilmet to improve glycaemic control in adults with type-2 diabetes when metformin with or without sulphonylurea and either Onglyza or Forxiga does not provide adequate glycaemic control, or when type-2 diabetes patients are already being treated with metformin, Onglyza and Forxiga.

Qtrilmet was approved in the US in May 2019 under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PG&E agreed to pay around $13.5 billion to settle all individual claims related to California wildfires, due to which the electric utility had to file for bankruptcy. With the Bankruptcy Court's approval of the settlement agreement, PG&E hopes to emerge from Chapter 11 by the June 30, 2020 deadline to participate in the State of California's go-forward wildfire fund. Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director...
Follow RTT
>